Jardiance gets parity with Farxiga in US as FDA clears use in heart failureEli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with Share XJardiance gets parity with Farxiga in US as FDA clears use in heart failurehttps://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/
Abbott bags FDA okay for AI-based heart imaging softwareThe FDA has approved an artificial intelligence-based imaging software developed by Abbott that is used to help physicians Share XAbbott bags FDA okay for AI-based heart imaging softwarehttps://pharmaphorum.com/news/abbott-bags-fda-okay-for-ai-based-heart-imaging-software/
Look out BMS, Cytokinetics has its eye on mavacamten’s turfShares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) Share XLook out BMS, Cytokinetics has its eye on mavacamten’s turfhttps://pharmaphorum.com/news/look-out-bms-cytokinetics-has-its-eye-on-mavacamtens-turf/
First US patient gets total heart replacement with CARMAT deviceAn experimental artificial heart developed by French medical device specialist CARMAT has been implanted into the first of Share XFirst US patient gets total heart replacement with CARMAT devicehttps://pharmaphorum.com/news/first-us-patient-gets-total-heart-replacement-with-carmat-device/
Novartis tries to rescue stalled inclisiran filing with FDANovartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on Share XNovartis tries to rescue stalled inclisiran filing with FDAhttps://pharmaphorum.com/news/novartis-tries-to-rescue-stalled-inclisiran-filing-with-fda/
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s JardianceAstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will Share XFarxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiancehttps://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/
Novo Nordisk crowns cell therapy pipeline with $598m Heartseed dealNovo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed Share XNovo Nordisk crowns cell therapy pipeline with $598m Heartseed dealhttps://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/
UK regulator backs Amarin’s cardiology drug VazkepaAmarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the Share XUK regulator backs Amarin’s cardiology drug Vazkepahttps://pharmaphorum.com/news/uk-drugs-regulator-backs-amarins-cardiology-drug-vazkepa/
Boehringer, Lilly’s Jardiance tries to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance tries to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
